PBT 2

Drug Profile

PBT 2

Alternative Names: PBT-2

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Prana Biotechnology
  • Class Antidementias; Dimethylamines; Hydroxyquinolines; Ionophores; Small molecules
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease

Highest Development Phases

  • Phase II Alzheimer's disease; Huntington's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in United Kingdom (IV, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in United Kingdom (PO, Suspension)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Huntington's-disease(In volunteers) in Netherlands (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top